Medicenna Therapeutics Corp. (TSX:MDNA)
Canada · Delayed Price · Currency is CAD | Market Cap | 40.61M -68.2% |
| Revenue (ttm) | n/a |
| Net Income | -18.56M |
| EPS | -0.22 |
| Shares Out | 92.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,796 |
| Open | 0.4500 |
| Previous Close | 0.4400 |
| Day's Range | 0.4400 - 0.4500 |
| 52-Week Range | 0.3350 - 1.7800 |
| Beta | 2.21 |
| Analysts | Strong Buy |
| Price Target | 3.20 (+627.27%) |
| Est. Earnings | Nov 13, 2026 |
About Medicenna Therapeutics
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkin... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MDNA stock is "Strong Buy." The 12-month stock price target is $3.20, which is an increase of 627.27% from the latest price.
News
Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
Updated data to be presented at SITC 2026; Company to host key opinion leaders webinar on November 10 Updated data to be presented at SITC 2026; Company to host key opinion leaders webinar on November...
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and suppress overactive immune cells responsible for inflammatory and autoimmune conditions by inhibiting IL-2 and IL...
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkin...
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
TORONTO and HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superki...
Medicenna Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Multiple clinical and regulatory milestones are expected in the next three to six months, including top-line data for MDNA11 and new data for bizaxofusp, both targeting significant unmet needs in oncology. The pipeline also includes first-in-class bifunctional and conditionally activated Superkines, with strong partnering and market potential.
Medicenna Therapeutics Slides: Corporate presentation
Medicenna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 16, 2026.
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference
Medicenna Therapeutics Report: Q1 2027
Medicenna Therapeutics published a report on August 13, 2026 containing material business information for investors and shareholders.
Medicenna Therapeutics MD&A: Q1 2027
Medicenna Therapeutics filed a regulatory document on August 13, 2026 disclosing important business information.
Medicenna Therapeutics Earnings release: Q1 2027
Medicenna Therapeutics released its Q1 2027 earnings on August 13, 2026, summarizing the period's financial results.
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer a...
Medicenna Therapeutics MD&A: Q4 2026
Medicenna Therapeutics filed a regulatory document on June 25, 2026 disclosing important business information.
Medicenna Therapeutics Report: Q4 2026
Medicenna Therapeutics published a report on June 25, 2026 containing material business information for investors and shareholders.
Medicenna Therapeutics Annual report: Q4 2026
Medicenna Therapeutics has published its Q4 2026 annual report on June 25, 2026.
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targe...
Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses Up to 80 patients with l...
Medicenna Therapeutics Transcript: Lytham Partners Spring 2026 Investor Conference
The conference highlighted a robust pipeline of engineered cytokine therapies targeting cancer and autoimmune diseases, with late-stage assets showing strong efficacy and safety. Multiple clinical and regulatory milestones are expected by 2027, supported by ongoing financing.
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Compa...
Medicenna Announces the Launch of a Marketed Public Offering of Securities
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Compa...
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/...
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
TORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superki...
Medicenna Therapeutics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
MDNA11 is showing strong response rates in solid tumors, with pivotal trial planning underway. MDNA113, a novel bispecific anti-PD-1, demonstrated superior safety and efficacy in preclinical models and is set for clinical entry by year-end. MDNA55 is advancing toward phase III with a partner.
Medicenna Therapeutics presents new preclinical data from MDNA113
Medicenna Therapeutics (MDNAF) presented new positive preclinical data from MDNA113, its first-in-class tumor-anchored and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine, at the Ameri...
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the dev...